Analyst Upgrades Signal Renewed Growth Cycle for Edwards Lifesciences Corporation (EW)

Group 1 - Edwards Lifesciences Corporation (NYSE:EW) is considered one of the best healthcare stocks to buy for 2026, with Stifel raising its price target to $110 from $105 while maintaining a Buy rating [1] - The price target increase is attributed to a significant rise in Transcatheter Aortic Valve Replacement (TAVR) procedures, indicating strong growth in the TAVR market fundamentals [2] - The company's revenue grew by 10% in the third quarter, primarily driven by the TAVR division, which constitutes 75% of total revenue, marking the strongest growth for this division in recent years [2] Group 2 - On January 9, TD Cowen upgraded Edwards Lifesciences to a Buy from Hold and raised the price target to $97 from $90, citing a renewed growth cycle driven by expanded indications for TAVR [3] - Edwards Lifesciences is a medical technology company focused on innovations for heart conditions, specializing in structural heart disease and critical care monitoring [4]